| Project/Area Number |
09670615
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | University of Tokushima |
|---|
Principal Investigator |
SHIMIZU Eiji University of Tokushima, School of Medicine, Lecturer, 医学部, 講師 (50187449)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAWANISHI Masashi University of Tokushima, School of Medicine, Asistant, 医学部, 助手 (90301316)
山本 晃義 徳島大学, 医学部・附属病院, 助手 (60284288)
|
|---|
| Project Period (FY) |
1997 – 1998
|
| Project Status |
Completed (Fiscal Year 1998)
|
| Budget Amount *help |
¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 1998: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1997: ¥2,400,000 (Direct Cost: ¥2,400,000)
|
|---|
| Keywords | Lung cancer / Oncogene / Tumor suppressor gene / p16, rb / Gene therapy / Chemotherapy / Pleuritis carcinomatosa / Cisplatin / p16 / RB / 抗癌剤感受性試験 / コロニー形成試験 |
|---|
| Research Abstract |
Treatment of inoperable lung cancer with pericarditis carcinomatosa consists of pleural administration of anticancer agents and/or inflammation-inducing agents, which have not improved the survival of the patients significantly because of poor local control and distant metastasis. Gene therapy for lung cancer using tumor suppressor gene including p53, rb, p16, an alternative of chemoimmunotherapy, which has recently developed in lung cancer, may improve the survival of the inoperable lung cancer patients with pleuritis carcinomatosa. In this study, we examined the basic and preclinical evaluation of rb and p16 in patients with carcinomatous pleural effusion. Under written informed consent, mononuclear cells were isolated from pleural effusion with seven patients with T4 status. Characteristics of patients include five males and two females/median age 72/6 adenocarcinomas and one small cell carcinoma. These samples formed 0-120 colonies per 200,000 mononuclear cells and five of seven patients were evaluable for antitumor
|
